Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P595 Feasibility and performance of a fully automated endoscopic disease severity grading tool for ulcerative colitis using unaltered multisite videos

ECCO'20 Vienna

Year: 2020
Authors:

R. Stidham1,2, H. Yao3, S. Bishu1, M. Rice1, J. Gryak3, H.J. Wilkins4, K. Najarian2,3,5

1University of Michigan, Department of Medicine - Division of Gastroenterology and Hepatology, Ann Arbor, USA, 2University of Michigan, Michigan Integrated Center for Health Analytics and Medical Prediction MiCHAMP, Ann Arbor, USA, 3University of Michigan, Department of Computational Medicine and Bioinformatics, Ann Arbor, USA, 4Lycera Corporation, Clinical Development, Plymouth Meeting, USA, 5University of Michigan, Department of Electrical Engineering and Computer Science, Ann Arbor, USA

P596 Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine

ECCO'20 Vienna

Year: 2020
Authors:

S. Timeus1, R. Laoun2

1Tillotts Pharma AG, Drug Safety, Rheinfelden, Switzerland, 2Tillotts Pharma AG, Medical Affairs, Rheinfelden, Switzerland

P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis

ECCO'20 Vienna

Year: 2020
Authors:

R. Besuyen1, D. Walker2, K. Winthrop3, M. Genovese4, B. Combe5, Y. Tanaka6, A. Kivitz7, F. Matzkies8, B. Bartok9, L. Ye10, Y. Guo10, C. Tasset1, J. Sundy11, E. Keystone12, R. Westhovens13, W. Rigby14, G. Burmester15

1Galapagos, Clinical Development, Mechelen, Belgium, 2Northumbria Healthcare, Department of Rheumatology, Northumbria, UK, 3Oregon Health and Science University, Department of Rheumatology, Portland, USA, 4Stanford University USA, Immunology and Rheumatology, Palo Alto, USA, 5CHU Montpellier University, Department of Rheumatology, Montpellier, France, 6University of Occupational and Environmental Health Japan, Department of Rheumatology, Kitakyushu, Japan, 7Altoona Center for Clinical Research USA, Clinical Research, Duncansville, USA, 8Gilead Sciences Inc., Medical Affairs, Foster City, CA, USA, 9Gilead Sciences Inc., Clinical development, Foster City, CA, USA, 10Gilead Sciences Inc., Biostatistics, Foster City, CA, USA, 11Gilead Sciences Inc., Clinical research, Foster City, CA, USA, 12Mount Sinai Hospital and University of Toronto Canada, Department of Rheumatology, Toronto, Canada, 13University UZ Leuven, Department of Rheumatology, Leuven, Belgium, 14Dartmouth College, Department of Rheumatology, Lebanon, NH, USA, 15Charité-University Medicine Berlin, Rheumatology and Clinical Immunology, Berlin, Germany

P598 Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme: An update as of May 2019

ECCO'20 Vienna

Year: 2020
Authors:

W.J. Sandborn MD1, J. Panés2, B.E. Sands3, W. Reinisch4, I. Modesto5, C. Su6, F. Steinwurz7, N. Lawendy6, N. Koram5, K. Kwok5, T.V. Jones6, A.J. Thorpe6, D. Quirk6, S. Danese8

1Division of Gastroenterology, University of California, San Diego- La Jolla- California, USA, 2Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Barcelona, Spain, Spain, 3Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, New York, New York, USA, 4Medical University of Vienna, Vienna, Austria, Austria, 5Pfizer Inc., New York, New York, USA, 6Pfizer Inc., Collegeville, Pennsylvania, USA, 7Unit of Inflammatory Bowel Disease- Hospital Israelita Albert Einstein, São Paulo, Brazil, Brazil, 8Humanitas University- IBD Center- Division of Gastroenterology, Rozzano, Milan, Italy

P599 Trimester exposure and pregnancy outcomes in women exposed to golimumab: Results from the company pharmacovigilance database

ECCO'20 Vienna

Year: 2020
Authors:

S. Esslinger1, M. Otero-Lobato1, S. Gabriel2, M. Clark3, P. Sheridan2, A. Geldhof1

1Janssen Biologics BV, Medical Affairs, Leiden, The Netherlands, 2Janssen LLC, Research and Development, Horsham, USA, 3Janssen LLC, Research and Development, Springhouse, USA

P600 Vedolizumab dose optimisation: Findings from a Belgian registry

ECCO'20 Vienna

Year: 2020
Authors:

E. Louis1, V. Muls2, P. Bossuyt3, A. Colard4, A. Nakad5, D. Baert6, F. Mana7, P. Caenepeel8, S. Vanden Branden9, S. Vermeire10, F. D’Heygere11, B. Strubbe12, A. Cremer13, J.C. Coche14, V. Setakhr15, F. Baert16, A. Vijverman17, J.L. Coenegrachts18, F. Flamme19, A. Hantson20, K. Wijnen20, E. Piters20, G. Hantsbarger21, P. Dolin22